Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürth – page 31

543 clinical trials in Fürth, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürth at a glance
543
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

543 trials in Fürth

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Pemphigoid

Not recruiting

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Malignant melanoma

Not recruiting

Study of Nivolumab for Patients with High-Risk Stage II Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Essen AöR

Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:University of Leipzig

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitaetsklinikum Essen AöR

Giant cell arteritis

Not recruiting

Study on the Effectiveness and Safety of Secukinumab for Patients with New-Onset Giant Cell Arteritis in Clinical Remission

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma GmbH

Study Comparing Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin versus High-Dose Chemotherapy with Paclitaxel and Drug Combination for Relapsed Germ Cell Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Universitaetsklinikum Ulm AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürth

What the registry says about research in the country

01 Breast Cancer Research

Innovative studies focusing on triple-negative breast cancer and HER2-negative variants, exploring new therapeutic approaches with targeted treatments.

  • Advanced treatment combinations
  • Maintenance therapy evaluation
  • Genetic mutation targeting

Multiple trials investigating novel drug combinations for improving patient outcomes.

02 Gastrointestinal Oncology

Research centered on colorectal cancer treatment, including studies for both early-stage and metastatic disease management.

  • Post-resection therapy optimization
  • Circulating tumor DNA analysis
  • Stage II cancer interventions

Examining innovative approaches to improve survival rates in colorectal cancer patients.

03 Cardiovascular Medicine

Studies addressing myocardial infarction and complex cardiac conditions, with emphasis on innovative therapeutic strategies.

  • STEMI treatment protocols
  • Anticoagulation management
  • Post-stent therapy optimization

Investigating new treatments for improved cardiac outcomes and reduced mortality rates.

04 Gynecologic Oncology

Advanced research in ovarian cancer treatment, focusing on maintenance therapy after initial treatment response.

  • Platinum-based therapy enhancement
  • Progression-free survival studies
  • Stage III/IV cancer management

Evaluating innovative maintenance treatments for advanced ovarian cancer patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.